EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma

  EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft
                                Tissue Sarcoma

PR Newswire

ROCKVILLE, Md., Jan. 23, 2013

ROCKVILLE, Md., Jan. 23, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a
clinical-stage pharmaceutical company, announced today the initiation of a
single-center Phase 2 study entitled "A Phase 2 Study of Oral ENMD-2076
Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma" at
Princess Margaret Hospital where the study is led by Malcolm Moore, MD and
Albiruni R.A. Razak, MD. The study is sponsored by Princess Margaret Cancer
Centre. More information about the clinical trial can be found at
www.clinicaltrials.gov.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

Albiruni R.A. Razak, MD, commented on the study, "Soft tissue sarcomas (STS)
are diverse mesenchymal tumors that commonly affect patients in the prime of
life. The prognosis for patients with advanced/metastatic sarcoma remains
poor and there are limited options for their treatment. The median disease
progression-free survival (PFS) for those patients is less than two months
without treatment or less than five months with treatments currently
available. This is certainly an area of unmet medical need. The primary
objective of this Phase 2 study is to evaluate the safety and efficacy of
ENMD-2076 in advanced/metastatic STS patients with the 6 month PFS rate as the
end point of the study. We will also perform biomarker correlative studies
that may define patients with a superior/inferior progression free survival. A
number of pre-clinical and clinical investigations have provided encouraging
results for the use of ENMD-2076 in the treatment of various types of cancer,
including sarcoma. We believe the co-inhibition of Aurora kinase A and
angiogenesis would render ENMD-2076 an attractive and logical treatment for
sarcoma."

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer commented, "We are
excited about the initiation of this trial. We believe ENMD-2076 has good
potential in the treatment of sarcoma along with other oncology indications.
In our Phase 1 trial in solid tumors, we had one patient with
advanced/metastatic sarcoma relapse after multiple lines of previous
therapies, however after being treated with ENMD-2076, the patient had
prolonged disease PFS for 21 months. This Phase 2 trial will enable us to
explore the potential of ENMD-2076 for this indication further. We look
forward to our continued advancement and development of ENMD-2076 as an
oncology platform."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market. Its lead compound, ENMD-2076, a
selective angiogenic kinase inhibitor, has completed several Phase 1 studies
in solid tumors, multiple myeloma, and leukemia, and is currently completing a
multi-center Phase 2 study in ovarian cancer. EntreMed, Inc. recently
announced the initiation of a Phase 2 study of ENMD-2076 in triple-negative
breast cancer and the initiation of a Phase 2 study of ENMD-2076 in
advanced/metastatic soft tissue sarcoma. Additional information about
EntreMed is available on the Company's web site at www.entremed.com and in
various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action.
ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine
kinase targets in addition to the Aurora A kinase. Aurora kinases are key
regulators of mitosis (cell division), and are often over-expressed in human
cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have
been shown to play important roles in the pathology of several cancers.
ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently
completing a Phase 2 trial for ovarian cancer. EntreMed, Inc. recently
initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative
breast cancer.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate; risks relating to the need
for additional capital and the uncertainty of securing additional funding on
favorable terms; declines in actual sales of Thalomid® resulting in reduced
royalty payments; risks associated with our product candidates; any
early-stage products under development; results in preclinical models are not
necessarily indicative of clinical results; uncertainties relating to
preclinical and clinical trials, including delays to the commencement of such
trials; the lack of success in the clinical development of any of our
products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks). Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition. We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at www.sec.gov.

COMPANY CONTACT:
Investor Relations
EntreMed, Inc.
240.864.2643
investorrelations@entremed.com

SOURCE EntreMed, Inc.

Website: http://www.entremed.com
 
Press spacebar to pause and continue. Press esc to stop.